Skip to main content

A Phase 2a, Open-label, Multicenter, Platform Trial to Assessthe Safety, Tolerability, and Efficacy of Inebilizumab andBlinatumomab in Subjects With Select Autoimmune Diseases

Open
  • Protocol code: 20240033 C
  • EudraCT code: No aplica
  • Research group: Rheumatology
  • Service: Rheumatology
  • Principal investigator:  Lopez Lasanta, Maria America
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase II